Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH

Blood (2019) 134 (Supplement_1): 3910.

https://doi.org/10.1182/blood-2019-127416

Published: 2019

Journal Articles

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

Mark J. Levis, MD, Mehdi Hamadani, MD, Brent R. Logan, Matt Rosales, David Delgado, Erkut Bahceci, Steven Devine, MD, Mary M. Horowitz, Yi-Bin Chen

Blood (2019) 134 (Supplement_1): 4602.

https://doi.org/10.1182/blood-2019-124322

Published: 2019

Journal Articles

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Jordi Esteve, MD PhD, Rik Schots, Teresa Bernal Del Castillo, MD PhD, Je-Hwan Lee, MD PhD, Eunice S. Wang, MD, Shira Dinner, MD, Mark D. Minden, MD PhD, Olga Salamero, MD, Jorge Sierra, MD, Goichi Yoshimoto, MD PhD, Kamel Laribi, MD, Janusz Halka, MD, Pau Montesinos, MD PhD, Shufang Liu, Elizabeth Shima Rich, MD PhD, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 2736.

https://doi.org/10.1182/blood-2018-99-110976

Published: 2018

Journal Articles

Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark J. Levis, MD, Tara L Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Chaofeng Liu, PhD MBA, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 564.

https://doi.org/10.1182/blood-2018-99-110975

Published: 2018

Journal Articles

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, MD, Joseph G. Jurcic, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Raoul Tibes, MD PhD, Jason E. Hill, PhD, Matt Rosales, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2018-99-110971

Published: 2018

Journal Articles

Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Keith Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark J. Levis, MD, Tara L. Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, Chaofeng Liu, PhD MBA, Erkut Bahceci, MD

Blood (2017) 130 (Supplement 1): 722.

https://doi.org/10.1182/blood.V130.Suppl_1.722.722

Published: 2017

Journal Articles

Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, Joseph G. Jurcic, MD, Ellen K Ritchie, MD, Stephen A Strickland, Raoul Tibes, Jason Hill, PhD, Shufang Liu, Erkut Bahceci, MD

Blood (2017) 130 (Supplement 1): 2705.

https://doi.org/10.1182/blood.V130.Suppl_1.2705.2705

Published: 2017

Journal Articles

Comparative Assessment of FLT3 Variant Allele Frequency By Capillary Electrophoresis and Next-Generation Sequencing in FLT3 mut+ patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Who Received Gilteritinib Therapy

Catherine C. Smith, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Andrew Carson, PhD, Jorge E. Cortes, MD, Timothy T Stenzel, MD PhD, Jason Hill, PhD, Qiaoyang Lu, MS, Erkut Bahceci, MD, Mark J. Levis, MD

Blood (2017) 130 (Supplement 1): 1411.

https://doi.org/10.1182/blood.V130.Suppl_1.1411.1411

Published: 2017

Journal Articles

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2016) 128 (22): 1069.

https://doi.org/10.1182/blood.V128.22.1069.1069

Published: 2016

Journal Articles

Understanding the Patient's Experience with Acute Myeloid Leukemia: A Patient Interview Study

Erin L. Tomaszewski, Catherine Fickley, PhD MPH, CPH, LeAnne Maddux, MA, Robert Krupnick, PhD, Erkut Bahceci, MD, Jean Paty, PhD, Floortje van Nooten, MSc

Blood (2015) 126 (23): 2121.

https://doi.org/10.1182/blood.V126.23.2121.2121

Published: 2015

Journal Articles

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

Tomoki Naoe, MD PhD, Toru Sakura, MD PhD, Yukio Kobayashi, MD PhD, Kensuke Usuki, MDPhD, Toshihiro Miyamoto, MD PhD, Hiroatsu Iida, MD PhD, Satoshi Morita, PhD, Erkut Bahceci, MD, Masahito Kaneko, RPh, Shunsuke Yamada, M.Eng, Shigeru Takeshita, MSc, Shuichi Miyawaki, MDPhD

Blood (2015) 126 (23): 1320.

https://doi.org/10.1182/blood.V126.23.1320.1320

Published: 2015

Journal Articles

Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study

Blood (2015) 126 (23): 321.

https://doi.org/10.1182/blood.V126.23.321.321

Published: 2015

Journal Articles

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study

Catherine C. Smith, MD, Mark J. Levis, MD PhD, Mark R Litzow, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Stanley C. Gill, PhD, Takeshi Kadokura, PhD, Geoffrey J. Yuen, Pharm.D., Ogert Fisniku, MS, Charles Liu, PhD, Itsuro Nagase, PhDDVM, Briana Sargent, BS, Noreen Welter, RN, BSN, Erkut Bahceci, MD

Blood (2015) 126 (23): 4836.

https://doi.org/10.1182/blood.V126.23.4836.4836

Published: 2015

Journal Articles

Significance of ELN Provisional Response Definitions In Predicting Long-Term Outcomes of Patients with CP-CML Treated with Dasatinib After Imatinib Failure.

Jorge E. Cortes, MD, Neil P. Shah, Charles A. Schiffer, Philipp D. LeCoutre, Priv.-Doz., Dr., med., Giuseppe Saglio, MD, PhD, Alfonso Quintás-Cardama, MD, Hagop Kantarjian, MD, Elias Jabbour, MD, Erkut Bahceci, Allen Chen, Alexandre Lambert, Francois Guilhot

Blood (2010) 116 (21): 3439.

https://doi.org/10.1182/blood.V116.21.3439.3439

Published: 2010

Journal Articles

Value of Survival Gains In Chronic Myelogenous Leukemia

Wesley Yin, John R Penrod, Ross Maclean, Jeffrey Humphrey, Erkut Bahceci, Darius Lakdawalla

Blood (2010) 116 (21): 4736.

https://doi.org/10.1182/blood.V116.21.4736.4736

Published: 2010

Journal Articles

Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib

Charles A. Schiffer, Jorge E. Cortes, Giuseppe Saglio, Philipp le Coutre, Francois Guilhot, Erkut Bahceci, David Dejardin, Neil P. Shah

Blood (2010) 116 (21): 358.

https://doi.org/10.1182/blood.V116.21.358.358

Published: 2010

Journal Articles

Assessing the Experience of Living with Chronic Myeloid Leukemia (CML) From the Patient's Perspective: Results of a Patient Survey

Timothy W Victor, Ph.D., Ishan Hirji, Ian Hicks, Jonathan Chapnick, Catherine Davis, PharmD, Erkut Bahceci, MD

Blood (2010) 116 (21): 4755.

https://doi.org/10.1182/blood.V116.21.4755.4755

Published: 2010

Journal Articles

Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation

Alfonso Quintás-Cardama, Hagop Kantarjian, Neil P. Shah, Charles A. Schiffer, Philipp le Coutre, Giuseppe Saglio, Francois Guilhot, Andreas Hochhaus, Martin C. Müller, Erkut Bahceci, Alexandre Lambert, Jorge E. Cortes

Blood (2010) 116 (21): 2297.

https://doi.org/10.1182/blood.V116.21.2297.2297

Published: 2010

Journal Articles

Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Elias Jabbour, Erkut Bahceci, Chao Zhu, Alexandre Lambert, Jorge Cortes

Blood (2009) 114 (22): 3296.

https://doi.org/10.1182/blood.V114.22.3296.3296

Published: 2009

NARROW

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study

Comparative Assessment of FLT3 Variant Allele Frequency By Capillary Electrophoresis and Next-Generation Sequencing in FLT3 mut+ patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Who Received Gilteritinib Therapy

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Understanding the Patient's Experience with Acute Myeloid Leukemia: A Patient Interview Study

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study

Significance of ELN Provisional Response Definitions In Predicting Long-Term Outcomes of Patients with CP-CML Treated with Dasatinib After Imatinib Failure.

Value of Survival Gains In Chronic Myelogenous Leukemia

Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib

Assessing the Experience of Living with Chronic Myeloid Leukemia (CML) From the Patient's Perspective: Results of a Patient Survey

Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation

Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only